Plain-English translation of NCT05696626 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two hormone-blocking treatment combinations for people with advanced breast cancer that has stopped responding to earlier treatments. One group will take lasofoxifene (the new medication being tested) plus abemaciclib, while the other group will take fulvestrant plus abemaciclib. The goal is to see which combination works better and is safer for patients whose cancer has a specific genetic mutation called an ESR1 mutation.
Some breast cancers develop a genetic change that helps them resist standard hormone treatments. This medication is designed to work differently against that change, potentially giving patients who have already tried other hormone therapies a better option.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. If assigned to the new treatment, you will take a daily oral medication (lasofoxifene) plus abemaciclib twice a day. If assigned to the comparison group, you will receive injections of fulvestrant on specific days plus take abemaciclib twice a day. You will have regular visits to monitor how well the treatment is working, check for side effects, and have blood tests and imaging scans. The trial involves 600 participants total and is currently recruiting.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States